Gordagen’s portfolio of pharmaceuticals and evidence-based nutraceuticals are based on natural tocotrienols (T3), which are found in small quantities in vitamin E in some plant oils. Studies to date highlight the potential for strong beneficial health effects and a good safety profile of tocotrienols.
T3 studies demonstrate the ability to:
The demonstrated health benefits of tocotrienols forms the basis of Gordagen’s product development portfolio.
Gordagen utilizes its unique formulation of T3, along with a proprietary melt-then-swallow technology (MELT3™), to unlock the full potential of tocotrienols. By overcoming T3’s tendency to rapidly degrade in the body, Gordagen’s MELT3™ technology provides far superior bioavailability when compared to commercially available formulations of T3.
The MELT3™ technology optimizes the bioavailability of T3, ensuring adequate amounts are exported into circulation and the target tissues. We believe this will translate to increased efficacy.
Gordagen’s innovative approach is working to develop the only evidence-backed melt T3 technology, initially providing pharmacy and sports store nutraceuticals for the active lifestyle and heart health markets.
The Company’s evidence-based nutraceutical clinical development program underpins and fast-tracks clinical development for our prescription pharmaceutical portfolio. This portfolio targets significant unmet medical needs, with the added benefit of generating substantial near-term revenues from nutraceuticals, starting 2016 and 2017.
Unhealthy eating habits and unfit lifestyles of many developed nations are leading to a considerable increase in chronic disease and premature death. Sedentary Death Syndrome is now recognized as a major public health burden, with prolonged inactivity leading to obesity, insulin resistance, cardiovascular disease, cancer, diabetes and musculoskeletal disorders.
Gordagen’s portfolio is targeted to assist in the promotion of active, healthy lifestyles to address this growing global problem. Our lead non-prescription products are initially addressing exercise endurance, delayed onset muscle soreness and heart health. The prescription portfolio is targeting a range of indications including: hyperlipidemia, diabetes, hypertension, pancreatic cancer, rheumatoid arthritis, non-alcoholic fatty liver disease, neuroprotection (MS) and bone health.